Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ZNTL zentalis.com
Zentalis Pharmaceuticals is a clinical-stage oncology company with no product revenue. Its development is focused on azenosertib (ZN-c3), an investigational, orally bioavailable, selective WEE1 kinase inhibitor.
The lead indication is Cyclin E1-positive platinum-resistant ovarian cancer (PROC), a biomarker-selected group making up about 50% of PROC patients. These patients have no specifically targeted approved therapy. The company uses a proprietary Cyclin E1 immunohistochemistry (IHC) assay and is pursuing companion diagnostic registration.
Clinical programs:
- DENALI: a registration-intended Phase 2 trial with FDA Fast Track Designation, aimed at potential accelerated approval.
- ASPENOVA: a randomized, confirmatory Phase 3 trial of about 420 patients comparing azenosertib with standard-of-care chemotherapy, designed for full approval in the U.S. and major ex-U.S. markets.
- MUIR: a Phase 1b study combining azenosertib with bevacizumab as maintenance therapy in platinum-sensitive ovarian cancer.
- A planned combination study in triple-negative breast cancer, including potential pairings with antibody-drug conjugates (ADCs).
More than 1,000 patients have been treated with azenosertib across tumor types. Zentalis is funded through equity offerings, including an August 2026 follow-on offering. Updated
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
Zentalis Pharmaceuticals is a clinical-stage oncology company with no product revenue. Its development is focused on azenosertib (ZN-c3), an investigational, orally bioavailable, selective WEE1 kinase inhibitor.
The Wall Street consensus 12-month price target for ZNTL is $7.44.